Symptom improvement with BDP/FF/G fixed triple inhalation powder in moderate to severe COPD patients uncontrolled with dual therapiesHarlander, Matevž (Avtor) Šubic, Tjaša (Avtor) Eržen, Renato (Avtor) Maček Cafuta, Arjana (Avtor) Lopert, Anton (Avtor) Horvat, Alojz (Avtor) Božič, Dušan (Avtor) Klobučar, Albert (Avtor) Krstić, Zoran (Avtor) Todorović, Nataša (Avtor) Sobotkiewicz, Nina (Avtor) Kirbiš, Simona (Avtor) Novakovič, Ana (Avtor) Šegota, Nikša (Avtor) Červenjak, Branislav (Avtor) Panjan Avramovič, Jasmina (Avtor) Paun, Kata (Avtor) Gabršček, Lucija (Avtor) chronic obstructive pulmonary diseasetherapyCOPD Assessment ToolPeople living with COPD are frequently inadequately treated due to underdiagnosis ormisdiagnosis. The aim of this study was to evaluate the real-world performance of thebeclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) fixed triplecombination formulated in a dry powder inhaler (DPI) in improving symptoms, lungfunction, and adherence in moderate to severe COPD patients uncontrolled on dualtherapies. We conducted a non-interventional, open-label, single-arm, multicenter,prospective study across 19 outpatient centers in Slovenia. The primary objective was tomeasure symptom improvement with the COPD Assessment Tool (CAT). A total of 359patients with moderate to severe COPD (97% classified as GOLD E, frequent exacerbators)were followed for 24 weeks. There was a significant 6-point reduction in the CAT score afterswitching from dual therapies to BDP/FF/G inhalation powder (95% CI: −7.0 to −5.5;p < 0.0001). FEV1 increased by 110 mL (95% CI: 90–130; p < 0.0001) and FVC by 95 mL (95%CI: 65–120; p < 0.0001), reaching a statistically significant improvement of 2.5 percentagepoints in the FEV1/FVC quotient. The net improvement in dyspnea severity was 50.9%(95% CI 44.7%–57.2%), as assessed using the modified Medical Research Council (mMRC)Scale. Treatment adherence improved significantly after 6 months of triple therapy. In ourcohort, switching uncontrolled moderate-to-severe COPD patients from dual therapy toBDP/FF/G fixed triple inhalation powder led to significant improvements in symptoms,lung function, dyspnea, sleep quality, and treatment adherence.20262026-08-24 09:31:36Neznano31978sl